Robert More

Bob earned his MBA at the University of Virginia's Darden School and his Bachelor's degree from Middlebury College. 

​

Bob is currently Chairman of One Revolution and the Foundation for Innovative New Diagnostics (FIND).

Bob More brings over 20 years of life sciences investing experience to his work at San Francisco-based Alta Partners. 

​

Most recently, Bob was a Senior Advisor to the Bill and Melinda Gates Foundation leading the organization's Global Health Venture Initiative. Earlier, Bob was a General Partner at Frazier Healthcare Ventures and a member of the firm's biopharma investment team. 

​

Prior to Frazier Healthcare, Bob was with Domain Associates where he started as a Kauffman Fellow in 1996 and became a Partner in 2000. From 1997-1998, Bob served as the Chief Operating Officer of Small Molecule Therapeutics, a Domain portfolio company subsequently purchased by Morphochem AG. Before his fellowship, Bob was with Pharmacia Biotech in sales, and also held a research position at Somatogen, a company developing a recombinant blood substitute that was subsequently bought by Baxter. While attending business school, Bob worked with MedVest, an early-stage venture group in Washington, DC. 

​

During his venture career, Bob has managed successful investments in and served on the boards of ESP Pharma (acquired by Protein Design Labs), Proxima Therapeutics (acquired by Cytyc), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan), IntraLase (acquired by Advanced Medical Optics), Oceana Therapeutics (acquired by Salix Pharmaceuticals), Achaogen (NASDAQ: AKAO), Neothetics, (NASDAQ: NEOT) and Glaukos Corporation (NYSE: GLKS). Bob was also an investor in Clovis Pharmaceuticals, Affinivax, and Sienna Labs.

Bob is a member of Kauffman Fellows Class 2 and served his fellowship under mentor Brian Dovey at Domain Associates in Princeton, NJ. He is a Kauffman Fellows founding board member, and has served as a mentor to Don O'Neil, Fellows Class 7.